

RESEARCH ARTICLE

Open Access

# Platelet adhesion and aggregate formation controlled by immobilised and soluble VWF



Matthias F. Schneider<sup>1†</sup>, Mohammad A. Fallah<sup>2†</sup>, Christian Mess<sup>3</sup>, Tobias Obser<sup>4</sup>, Reinhard Schneppenheim<sup>4</sup>, Alfredo Alexander-Katz<sup>5</sup>, Stefan W. Schneider<sup>3</sup> and Volker Huck<sup>3,6\*</sup> 

## Abstract

**Background:** It has been demonstrated that von Willebrand factor (VWF) mediated platelet-endothelium and platelet-platelet interactions are shear dependent. The VWF's mobility under dynamic conditions (e.g. flow) is pivotal to platelet adhesion and VWF-mediated aggregate formation in the cascade of VWF-platelet interactions in haemostasis.

**Results:** Combining microfluidic tools with fluorescence and reflection interference contrast microscopy (RICM), here we show, that specific deletions in the A-domains of the biopolymer VWF affect both, adhesion and aggregation properties independently. Intuitively, the deletion of the A1-domain led to a significant decrease in both adhesion and aggregate formation of platelets. Nevertheless, the deletion of the A2-domain revealed a completely different picture, with a significant increase in formation of rolling aggregates (gain of function). We predict that the A2-domain effectively 'masks' the potential between the platelet glycoprotein (GP) Ib and the VWF A1-domain. Furthermore, the deletion of the A3-domain led to no significant variation in either of the two functional characteristics.

**Conclusions:** These data demonstrate that the macroscopic functional properties i.e. adhesion and aggregate formation cannot simply be assigned to the properties of one particular domain, but have to be explained by cooperative phenomena. The absence or presence of molecular entities likewise affects the properties (thermodynamic phenomenology) of its neighbours, therefore altering the macromolecular function.

**Keywords:** Von Willebrand factor, Platelet adhesion, Shear activation, Primary haemostasis

## Background

The shear dependent role of von Willebrand factor (VWF) during primary haemostasis is very well established and investigated [1–10]. Understanding the VWF function is consisted of the physical aspects of hydrodynamics and structural conformations, and physiological aspects

ranging from the underlying molecular biology to its functional characteristics and clinical impact.

Clinically, both qualitative (Type II) and quantitative (Type I and III) VWF variants are classified in the framework of von Willebrand disease (VWD) [11–13]. VWD as a hereditary disease is a common bleeding disorder caused by mutations of VWF resulting in deficiency or dysfunction of this biopolymer. In addition, the acquired von Willebrand factor syndrome (AVWS), reviewed by Tiede and coworkers, subsumes diverse non-inherited qualitative, structural or functional VWF disorders resulting in an enhanced risk of bleeding [14, 15]. The hereditary VWD certainly affects both the immobilised and the soluble VWF fractions, whereas

\* Correspondence: [v.huck@uke.de](mailto:v.huck@uke.de)

<sup>†</sup>Matthias F. Schneider and Mohammad A. Fallah contributed equally to this work.

<sup>3</sup>University Medical Centre Hamburg-Eppendorf, Centre for Internal Medicine, Martinistr. 52, 20246 Hamburg, Germany

<sup>6</sup>Heidelberg University, Medical Faculty Mannheim, Experimental Dermatology, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

AVWS leads to an impact only on the mobile fraction. Although the first step of haemostasis depends on the presence of an intact immobilised binding partner for platelets in the subendothelial vessel wall [16–18], bleeding episodes of patients suffering from AVWS illustrate that the mobile VWF fraction is a prerequisite for an effective VWF triggered blood clotting. Independent of the different pathomechanisms and clinical manifestations, the similar symptomatic therapeutic regimens of these syndromes underline the central role of VWF's functional characteristics.

Bridging the gap between VWF's clinical impact and its physical mechanistic background, former studies on single VWF molecules under flow [9, 19] as well as on its collective behaviour [20–23] have further elucidated the role of VWF while in motion. The impact of specific VWF domains on its main binding partners in the human vasculature, such as VWF itself [24–26], collagen [27, 28] and in particular platelets via shear-dependent VWF A1-domain to glycoprotein (GP) Ib interactions [24, 29, 30], have been investigated in detail for both realising basal mechanistical insights and as potential therapeutic targets in the wide field of haemostaseology.

In this study, we combined a microfluidic setup with fluorescence- and reflection interference contrast microscopy (RICM) (see Fig. 1) to compare the impact of various deletions on VWF's A-domain on the physiological function of both immobilised and soluble VWF. Large VWF-platelet-aggregates of several 100  $\mu\text{m}$  in size, formed *reversibly* above a critical shear threshold, begin to roll on the surface of a microfluidic channel under whole blood conditions [31, 32]. These data demonstrate once more the importance to approach blood clotting as a dynamic process, in which in general important conformations - or better states - of all contributing constituents are a function of all physical (here shear flow) and biochemical (e.g. pH, multimer size) conditions. Systematically deleting the A1-, A2- or A3-domain of the surface-bound (immobilised) and mobile (soluble) VWF fraction, while studying platelet adhesion and reversible VWF-platelet aggregate formation over a wide range of shear rates, revealed the non-trivial interrelation between these domains, and showed that similar adhesion characteristics can be accompanied by a significant shift in aggregation tendency depending on the specific mutation.

## Results

### Platelet adhesion on immobilised VWF

Focusing on the shear conditions present in the human microvasculature [33] we applied shear rates between  $500\text{ s}^{-1}$  and  $10,000\text{ s}^{-1}$ . Figure 2 plots the adhesion of platelets under low shear conditions as a function of time for the three different VWF A-domain deletion variants (del-A1, del-A2, del-A3) in the absence of soluble


VWF. Whereas biofunctionalisation with wt VWF led to a time-dependent increase in platelet adhesion, coating with del-A1 VWF mutant failed to bind platelets, comparable to biofunctionalisation with bovine serum albumin (BSA) serving as negative control. Albeit the complete deletion of entire subdomains, there was no significant difference between del-A3 and wt VWF. The slight change of platelet adhesion to del-A2 remained negligible compared to the wildtype glycoprotein. These platelet adhesion characteristics were quantified by the surface coverage (SC) of platelets at the footprint of the biofunctionalised channels relative to wt VWF as previously published [34] (see Fig. 2b).

Keeping the immobilised VWF fraction unchanged, we next addressed the role of soluble VWF in the process of platelet adhesion. Therefore, we performed flow experiments on channels biofunctionalised with wt VWF, with or without addition of mobile wt VWF at distinct shear rates in the range of  $1000\text{ s}^{-1}$  to  $10,000\text{ s}^{-1}$ . As shown in Fig. 3, there were no qualitative differences between these experimental groups regarding the platelet SC at low shear rates (Fig. 3a). But interestingly, at higher shear rates platelets could only adhere to the immobilised VWF in the presence of soluble VWF (Fig. 3b and c), quantified in Fig. 3d. These data illustrate that the mobile VWF fraction is a prerequisite for platelet adhesion under high-shear conditions.

### Collective behaviour: mobile VWF-induced aggregate formation

Recently we could show that under whole blood conditions large VWF-platelet aggregates reversibly formed above a critical shear threshold rolling alongside the surface of a microfluidic channel [31, 32]. For the process of rolling aggregate formation see Fig. 4 and the RICM time-lapse live-cell movie (Additional file 1).

In Fig. 5a, a sequence of images along increasing shear rates is shown, where in addition to surface-bound immobilised VWF, VWF was also present in solution (mobile). Deletions of an individual domain showed distinct consequences on the aggregate formation: While A1-deletion mutant completely failed to induce VWF-platelet aggregates on an intact wt VWF biofunctionalised surface, the A2- and A3-deletion mutants are capable of aggregate formation. Compared to addition of wt VWF, del-A2 formed aggregates even at lower shear rates, clearly indicating a gain of function. A meaningful quantitative measure of aggregate formation has been shown to be the critical shear rate ( $\gamma_{crit}$ ), which in principle determines a nucleation point [20]. To quantify  $\gamma_{crit}$  next to the optical identification of first rolling aggregates (see Fig. 5a, red circles), we plotted the RICM signal intensities of aggregated platelets against the time, here representing distinct shear rates (Fig. 5b).




Maximum fluctuations in the intensity plots correspond to  $\gamma_{crit}$ .

### Discussion

In this study, it was clearly shown that, in order to determine the influence of VWF in the first step of haemostasis, solely the quantification of the platelet adhesion – using in vitro standard procedures – is not sufficient.

Only the comprehension of the biophysical component of the fluid dynamics on the one hand, the integration of both collective and single molecule phenomena on the other hand, and finally the distinction between immobilised and soluble VWF opens up the possibility for a targeted investigation of the mechanistic background.


Platelet adhesion on immobilised VWF is a time dependent process. To study the initial step of platelet



**Fig. 2** Platelet adhesion on immobilised VWF. **a** After biofunctionalisation of the microfluidic channels with the three different VWF A-domain deletion variants or wt VWF, the adhesion characteristics of platelets are measured upon constant shear rate application of  $500 \text{ s}^{-1}$  at indicated points in time. Representative images out of four independent experiments for each group are depicted. As expected, coating with wt VWF leads to an increasing platelet adhesion over time. Del-A1 VWF coating fails to bind platelets. The slight change of platelet adhesion to del-A2 remained negligible compared to the wt VWF. Platelet adhesion to del-A3 coating is similar to wildtype. Biofunctionalisation with BSA serves as negative control. Scale bars correspond to  $100 \mu\text{m}$ . **b** The relative platelet surface coverage (SC) to wt VWF on indicated biofunctionalisation is plotted against time. Wt VWF (black column), del-A3 (grey column) and del-A2 (red column) show similar platelet adhesion characteristics over time. Del-A1 (green column) nearly fails to bind platelets comparable to BSA serving as negative control (data not shown).  $n > 4$  for each experimental group, \* indicates  $P < 0.05$

adhesion due to interactions of the VWF A1-domain and the platelet glycoprotein (GP) Ib, platelet activation was inhibited as previously described [35]. Thus, platelet-derived VWF was excluded as a further source of the mobile VWF fraction. As expected,

biofunctionalisation with the deletion mutation del-A1 succeeded in coating but completely failed to bind platelets. Regarding the platelet adhesion capability on immobilised VWF, the deletion mutations del-A2 and del-A3 did not show any significant variation compared to wt



VWF. As bleeding events are known to cause pathological high-shear conditions in the area directly affected by the damaged vessel [36], we next focused on short-termed VWF-platelet interactions upon different shear flow regimens. High shear rates in human arterioles range around a few  $100\text{ s}^{-1}$  to  $1000\text{ s}^{-1}$  [33, 37, 38], and shear supported (human) platelet adhesion has been demonstrated to be effective already in the range of  $500$

$\text{s}^{-1}$  [9, 31, 39]. Under low- or intermediate-shear conditions, the impact of the mobile VWF fraction on platelet adhesion to VWF biofunctionalised surfaces was negligible. Nevertheless, in the entire absence of soluble VWF, platelet binding to the surface was significantly diminished upon high-shear application (see Fig. 3). In contrast, in the presence of soluble VWF rising shear led to an enhanced platelet adhesion. In accordance with




Fig. 4 (See legend on next page.)

(See figure on previous page.)

**Fig. 4** and Additional file 1 The process of aggregate formation on a wt VWF coated channel footprint. An RICM time-lapse live-cell movie (Additional file 1) is recorded at the footprint of a wt VWF biofunctionalised channel perfused with whole blood supplemented with wt VWF. The bright contrasted objects in the focal plane are platelets interacting with VWF at the channel surface. Note that only events in the direct adjacency to the focal plane are visible in RICM. Upon continuously increasing the shear rate within the first 35 s, the pattern of single rolling platelets switches to platelet decorated string-like structures ( $\sim t = 20$  s) which progressively stretch in flow. After some of these strings detach and first aggregates emerge (at the critical shear rate of  $4000 \text{ s}^{-1}$ ), the flow was stopped leading to an immediate disassembly of strings and aggregates. From  $t = 37$  s, we restart the flow with a constant shear rate of  $4000 \text{ s}^{-1}$ , resulting in re-formation of aggregates rolling along the surface. Still images at  $t = 56$  s (**a**),  $t = 59$  s (**b**) and  $t = 62$  s (**c**) illustrate the tracking of one exemplarily chosen rolling VWF-platelet aggregate (red circles). Time frame in seconds as indicated, scale bar corresponds to  $50 \mu\text{m}$

former publications [40, 41], platelet decorated strings appear within seconds (see Electronic Supplementary Material 1), most likely due to a recruitment of stretched mobile VWF to the platelet surface. The further *fortune* of the formed reversible aggregates – assuming constant hypercritical shear conditions – will indeed be influenced by further VWF-VWF [25, 26, 42] and VWF-platelet interactions [23, 29, 30] as well as by a subsequent activation of the involved platelets. But focusing on the mechanistical background of the very initial step of the reversible rolling aggregate formation process, namely the physically-driven collective phenomena of VWF, these aspects should be discussed in future studies.

Although single platelet adhesion to the channel footprint and consecutive recruitment of soluble VWF are the likely prerequisites for aggregate formation, adhesion characteristics have no predictive power for the formation of rolling VWF-platelet aggregates. In a previous study, a truncated recombinant A1A2A3 tri-domain VWF was reported to have enhanced interactions with platelets compared to the full-length recombinant tri-domain VWF [22]. The truncated tri-domain VWF had a deletion of Gln<sup>1238</sup>-Glu<sup>1260</sup> sequence of the flanking A1-domain. The deletion was reported to reduce the ‘masking’ effect of the VWF D’D3-domain on the GPIIb interactions with VWF. In our work, the deletion of the A2-domain does not affect the platelet adhesion to immobilised VWF, nevertheless enhancing the formation of reversible VWF-platelet aggregates in the presence of a soluble VWF fraction. This indicates that the A2-domain also masks the reversible interactions of the platelets with the A1-domain of VWF. Our finding becomes more significant considering the fact that it has been previously reported that recombinant A2-domain polypeptides bind specifically to the VWF A1-domain [24]. This binding inhibits platelet adhesion by blocking the specific binding site of the A1-domain to the platelet GPIIb. We could show for the selected deletion variants of the A-subdomains of VWF that a deletion of the A1-domain indeed led to a significant decrease in adhesion and a complete loss of aggregate formation. Nevertheless, while the impact of the A3-domain on adhesion and aggregate formation seemed to be marginal, a deletion of the A2-domain – although leading to a negligible

change in platelet adhesion – induced a significant reduction in  $\gamma_{crit}$  i.e. an increase in the formation of VWF-platelet aggregates. Note that due to the absence of divalent cations during the whole course of microfluidic experiments, the activity of the VWF degradation enzyme ADAMTS-13, known to specifically interact with the VWF A2-domain, is inhibited to facilitate the concentration on the VWF interdomain affection. Although one could raise the hypothesis that adhesion and aggregate formation are regulated by specific binding sites on different parts along the molecule (e.g. the collagen binding site of the A3-domain) [43, 44], we here prefer to look at this molecule from a different more physical angle:

Our results strongly support a hypothetical scenario suggested earlier by Ruggeri et al. [6]: Single platelets tethered to immobilised VWF function as nucleation centres. Soluble VWF binds to the immobilised platelet, in particular under high shear flow, thereby representing a nucleation centre itself supporting the growth of the aggregate. The aggregate formation can be explained by a three-step process and the “matching” of two time-scales. First, the elongational contribution of the shear field supports the elongated state of VWF (Fig. 6a). The shear field also introduces the first timescale  $\tau_{rot} \approx 1/\dot{\gamma}$  ( $\gamma$  representing the shear rate), the period of one rotation of a platelet exposed to the field. The second timescale  $\tau_{bind}$  arises from the binding kinetics and corresponds to the time the elongated VWF typically resides on the platelet. Of course, in reality, all these quantities are thermodynamic quantities and will vary with temperature, pH, ion concentrations etc. in other words they are represented by their appropriate diagrams of state [45]. Nevertheless, if  $\tau_{rot} < \tau_{bind}$  the VWF will reside long enough on the platelet to wrap around it (Fig. 6b). This will effectively coat the platelets due to the enlarged contact area. Via VWF-VWF interactions the platelets can now begin to form aggregates, given a high enough concentration of platelets (Fig. 6c).

We must note that a recent work explaining how VWF adheres to surfaces at high shear rates can also be used to explain why aggregate formation occurs only in the presence of soluble VWF [46]. In particular, at shear




Fig. 5 (See legend on next page.)


(See figure on previous page.)

**Fig. 5** Critical shear rate of rolling aggregate formation depends on mobile VWF fraction. After biofunctionalisation with wt VWF, channels are perfused with whole blood supplemented with indicated mobile VWF variant and observed using RICM. The critical shear rate for VWF-platelet aggregate formation is analysed by consecutively increasing the shear from  $1000 \text{ s}^{-1}$  to  $5000 \text{ s}^{-1}$  in steps of  $500 \text{ s}^{-1}$  (a) Whereas the VWF A1-domain deletion completely fails to induce rolling aggregates, del-A2 shows a gain of function by decreasing the critical shear compared to wt VWF; del-A3 does not influence the critical shear rate. Red-arrowed circles illustrate aggregates rolling on the surface in the marked direction. In the right column, magnifications of rolling aggregate regions at the critical shear rate are depicted if available. Scale bars correspond to  $50 \mu\text{m}$ . (b) The RICM signal intensities (MI [AU]) for wt VWF (black line), del-A1 (green line), del-A2 (red line) and del-A3 (grey line) of the VWF-platelet aggregates are plotted against the time, representing distinct shear rates as indicated. Maximum fluctuations in the intensity plots correspond to the critical shear rate  $\dot{\gamma}_{crit}$ . The analysed  $\dot{\gamma}_{crit}$  for del-A2 VWF is about 40% less than for wt VWF. Note that the detection of fluctuations as transition point representing  $\dot{\gamma}_{crit}$  has two consequences: 1. The plotted intensities have to be representative tracings out of four independent experiments for each group as a graphical overlay would naturally mask this transition point. 2. With the discrete step width of  $500 \text{ s}^{-1}$  the single experiments of each experimental group showed exactly the same depicted transition point. Therefore,  $\dot{\gamma}_{crit}$  for del-A2 is significantly lower than  $\dot{\gamma}_{crit}$  for wt VWF and del-A3 VWF. While the certainty is predominantly determined by the step width, we avoid indicating a  $P$  value

rates above  $1000 \text{ s}^{-1}$ , platelets are exposed to shear forces in the range above of  $10 \text{ pN}$ . This force is around the rupturing force of the GPIb-A1 bond [47]. Thus, in excess of this force platelets need a cooperative mechanism to bind. By forming aggregates, it is possible to overcome this limit since the binding to the substrate leads to a higher valence arising from the other platelets on the string. As long as the lifetime of the bonds is long enough, such aggregates will be able to bind and immobilise on the substrate.

The gain of function observed during aggregate formation for the del-A2 mutations reveals that the simple picture of altered VWF-platelet association (Fig. 2) leads to a false prediction of the aggregation behaviour. As

shown in Fig. 5, the threshold shear rate at which aggregates form for wt VWF is of the order of  $4000 \text{ s}^{-1}$ ; however, in the case of the deletion of the A2-domain it is  $2500 \text{ s}^{-1}$ . The  $\sim 40\%$  change in this threshold shear rate can be accounted by an increase in the binding strength between the A1-domain and the platelet GPIb receptor. As has been previously speculated, we can confirm that the GPIb-A1 interaction is regulated by the presence of the A2-domain [21, 48]. It is believed that the interaction is masked by the A2-domain yielding an effective lifetime of the GPIb-A1 bond that displays a “catch-bond” behaviour [25, 29, 30]. In the absence of the A2-domain, the lifetime at lower shear forces of the GPIb-A1 bond was radically increased. By how much? Based



**Fig. 6** Proposed mechanism of aggregate formation. **a VWF stretching.** Conformation of a single VWF molecule changes under high shear flow conditions from globular to elongated form. **b Cooperative association.** Stretched VWF binds to a rotating platelet. Only if the bond-lifetime  $\tau_{bind}$  is sufficiently long ( $\tau_{bind} > \tau_{rot}$ ) compared to the period of rotation  $\tau_{rot}$ , VWF will begin to “wrap” around the platelet. This will allow forming multiple bounds, which stabilises the association against shear induced bond dissociation. **c Aggregate formation.** Partially VWF coated platelets will cross-interact with further platelets. If the platelet concentration  $C_{platelets}$  and hence collision rates are sufficient, this will initiate the reversible formation of aggregates

on our previous work on aggregate formation [20], it is possible to measure such differences. In particular, in order to reduce the critical shear rate by  $x$ , the lifetime of the GPIb-A1 has to increase by the same factor  $x$ . By assuming that all prefactors remain the same, we find that the effective interaction strength between the GPIb and the A1-domain has to increase by  $\sim 1$  kT, where  $k$  is the Boltzmann constant and  $T$  the temperature.

Such variation is small, yet has a dramatic impact on the clotting process. Thus, we predict that the A2-domain effectively “masks” the potential between the GPIb and the A1-domain by about 1 kT. While it would be hard to resolve an interaction energy of this magnitude, this change should not carry over into the high-shear regimen as the shear forces will already be enough to pull apart the domains and reduce the masking ability of the A2-domain.

## Conclusions

The results of our *in vitro* study contribute to a deeper understanding of the stepwise process of VWF activation and further clarify the impact of mobile VWF-initiated aggregate formation in the cascade of VWF-platelet interactions. Taken together, these findings call for a thermodynamic approach to understand VWF triggered blood clotting where the mechanical perspectives recently discovered [9, 49–53] are only a way towards an integrative perspective. In future, therefore it will be necessary to extract the phenomenology of VWF, here the changes of the protein's state upon deletion mutations, by experiments, which are analysed thermodynamically and are the basis of a physical explanation of biological function as well as a gain to new insight on a microscopic scale.

## Methods

### Microfluidic channel system

The fluid dynamic conditions of the human microvasculature, was mimicked in a pneumatically driven microfluidic channel system (BioFlux, San Francisco, California, USA). The BioFlux system is a bench-top instrument, which allows long-term temperature-controlled flow cell assays. Its pressure interface connects a high precision electropneumatic pump to the well plates to initiate controlled flow rates with a nominal shear rate precision of  $36 \text{ s}^{-1}$ . The channel geometry is a straight rectangular duct with a width of  $350 \mu\text{m}$  and a height of  $75 \mu\text{m}$ . Biofunctionalisation succeeded by coating the channels with either wildtype von Willebrand factor (wt VWF) or a deletion mutant VWF in a concentration of  $50 \mu\text{g/ml}$  each. A homogenous coating, representing the immobilised VWF at the extracellular matrix of a subendothelial vessel wall, was achieved after

incubation over night at  $37^\circ\text{C}$  in a moisture rich environment as previously published [20].

### Microscopic setup

The microfluidic channel system was mounted onto an inverted microscope (Zeiss Axio Observer Z.1, Zeiss AG, Oberkochen, Germany) operated in either fluorescence- or RICM-mode, respectively. RICM is especially beneficial for studying both dynamic and static biological phenomena taking place in vicinity of a transparent substrate, especially under whole blood experimental conditions. This microscopy mode is used to study the interference pattern of polarised incoming light being reflected at an object in order to reconstruct the height profile of the object at an interface as previously published [20]. Briefly, the interference of the object beam and the reference beams provides an image depicting sample's height profile with high resolution. The reduction of scattered light succeeded in utilising the antiflex technique, in which the incident light passes a linear polariser. Therefore, the RICM technique assures detection of the platelet membrane coming in direct contact with the observed surface in a high spatial resolution [54]. This specific microscopy technique succeeded by an adapted utilisation of a 63fold antiflex EC Plan-neofluar objective, a reflector module Pol ACR P&C for HBO and a LED module Colibri illumination at  $470 \text{ nm}$  (all Zeiss AG, Jena, Germany). A sketch of this combined microfluidic/microscopic setting is shown in Fig. 1. Image acquisition was performed using a CCD camera (AxioCam MrM) and ZEN software (both Zeiss AG, Jena, Germany).

### Cell culture and expression of recombinant wildtype and deletion mutant VWF

For recombinant VWF expression, we used HEK293 cells (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany) as previously published [55]. In brief, cells were cultured in Dulbecco Modified Eagle Medium (DMEM, Invitrogen, Karlsruhe, Germany) supplemented with 10% foetal bovine serum and 1% penicillin/streptavidin at  $37^\circ\text{C}$  and transfected with Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) and VWF-plasmid-constructs in vector pIR-ESneo2. Recombinant expression of VWF variants was performed as previously described [56]. In brief, HEK293 cells stably express wt VWF or indicated deletion mutants. Samples of the supernatant were taken after 72 h, centrifuged (5 min at  $270 \text{ g}$ ,  $4^\circ\text{C}$ ) and concentrated with Amicon Ultrafree-15. The concentration of wt VWF, del-A1 (p.Glu1260\_1480del) VWF, del-A2 (p.Asn1493\_1673del) and del-A3 (p.Gly1672\_1874del) VWF was determined by a polyclonal rabbit anti-human VWF:Ag-ELISA (DAKO, Hamburg, Germany). For a

detailed description of its binding epitopes refer to Tan et al. [57].

### Preparation of the perfusion media

For preparation of the perfusion media, blood was smoothly collected from healthy volunteers after informed consent. We utilised sodium citrated monovettes with manual syringe stamps to avoid platelet preactivation and further inhibit the activity of inherent degradation enzymes (e.g. ADAMTS-13). This study, approved by the Ethics Committee II of the Heidelberg University (Mannheim, Germany), was conducted in conformity to the *Declaration of Helsinki* [58], to *The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)* Guidelines and to the Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (Oviedo, 4 April 1997).

Platelets were isolated from blood samples, washed and fluorescently stained as previously published [35]. These platelets were resuspended in divalent cation free phosphate-buffered saline solution and used for perfusion in a concentration of 200,000 per  $\mu\text{l}$  supplemented with 45% haematocrit. Alternatively, the blood samples were natively perfused as citrate-anticoagulated whole blood supplemented with wt VWF or deletion mutant VWF as indicated.

### Experimental procedure

Under physiological conditions, VWF comes into effect in both the extracellular matrix of the subendothelial vessel wall (immobilised) and the circulating plasma (soluble) [4, 6–8]. Three sets of experiments were designed to discretely mimic the complex physiology of VWF mediated platelet adhesion and VWF-platelet aggregate formation in vitro:

1. In order to investigate the impact of deletions in the VWF A-domains on platelet adhesion, microfluidic channels were biofunctionalised with indicated deletion mutant VWF and perfused with washed platelets supplemented with 45% haematocrit as described above at a shear rate of  $500\text{ s}^{-1}$ . After 1, 5 and 10 min of perfusion, platelet adhesion was studied by fluorescence microscopy using a Zeiss 10fold objective compared to platelet adhesion on wt VWF biofunctionalisation. Note that no soluble VWF was present in these experiments.
2. Addressing the impact of immobilised and soluble VWF on platelet adhesion under physiological and pathological flow conditions, channels were biofunctionalised with wt VWF. Then, we perfused

the channels with the washed platelet solution supplemented with 45% haematocrit as described above with or without addition of  $10\text{ }\mu\text{g/ml}$  wt VWF. Perfusion was performed at distinct shear rates in the range of  $1000\text{ s}^{-1}$  to  $10,000\text{ s}^{-1}$  for 5 min. Live cell fluorescence videos were recorded with four frames per second using a Zeiss 20fold objective and analysed as described.

3. To study VWF-platelet aggregate formation, channels were biofunctionalised with wt VWF as described above. The biofunctionalised channels were perfused with native citrate-anticoagulated whole blood, additionally supplemented with indicated A-domain deleted VWF thus raising the collective VWF concentration to  $50\text{ }\mu\text{g/ml}$ . The aggregation behaviour, namely the critical shear rate necessary for the formation of VWF-platelet aggregates, was then monitored as previously published [20]. Briefly, the shear rate was consecutively increased from  $1000\text{ s}^{-1}$  to  $5000\text{ s}^{-1}$  in discrete steps for 30 s each, and RICM movies were recorded with two frames per second using a specialised Zeiss 63fold antireflective objective. VWF-platelet aggregates consisting of at least 15 platelets rolling at the channel footprint were considered rolling aggregates. We determined the critical shear rate for formation of these whole blood/A-domain deleted VWF aggregates compared to those of whole blood supplemented with wt VWF. For each experiment of the aforementioned settings at least four independent experiments were performed.

### Image analysis and statistical computation

For image analysis, we used ZEN software (Zeiss AG, Jena, Germany). Calculation and quantification of the platelet SC succeeded using the open-source software ImageJ (V. 1.46r, National Institute of Health, Bethesda, Maryland, USA) analysing five randomly chosen contrast-normalised fields of view at each indicated point in time of each independent experiment. Quantification of the RICM signal intensity was also performed using ImageJ analysing contrast-normalised fields of view at each indicated point in time of each independent experiment, plotted against the time. Mean data of experiments are given with standard deviation (SD). Statistical computation was performed with SAS 9.2 (SAS Institute Inc., Cary, North Carolina, USA). Statistical significance was tested by the unpaired Student's t-test. Significant differences of compared values are indicated by \* ( $P < 0.05$ ).

### Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12860-020-00309-7>.

**Additional file 1.** (WMV 8497 kb)

### Abbreviations

AVWS: acquired von Willebrand factor syndrome; BSA: bovine serum albumin; DFG: German Research Foundation; GP: glycoprotein; ICH: The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; RICM: reflection interference contrast microscopy; SC: surface coverage; SD: standard deviation; VWD: von Willebrand disease; VWF: von Willebrand factor; wt: wildtype;  $\gamma_{crit}$ : critical shear rate

### Acknowledgements

Not applicable.

### Authors' contributions

MFS designed and directed research and wrote the manuscript. MAF performed experiments, analysed experimental data and wrote the manuscript. CM developed and performed computational analyses of the dataset and carried out the statistical evaluation. TO and RS developed, expressed and provided recombinant genetic constructs. AA-K helped in interpreting the biophysical data. SWS directed research and supervised experiments. VH designed and directed research, supervised experiments, analysed experimental data and wrote the manuscript. All authors have read and approved the manuscript.

### Funding

The study was funded by the German Research Foundation (DFG) through the projects SFB/Transregio 23 (SWS TP A9) and SHENC - Research Unit FOR1543 (VH/SWS TP A2, MAF/MFS TP B1, RS TP A1 and MFS for a Guest Professorship). The funding body naturally affected the topical focus of our applied research field without influencing the specific design of the present study, the collection, analysis, and interpretation of data and writing the manuscript. Open access funding provided by Projekt DEAL.

### Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

### Ethics approval and consent to participate

All procedures performed in studies involving human participants were conducted in conformity to the *Declaration of Helsinki* [58] and to *The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)* Guidelines (<http://www.ich.org>), accessed in October 2019. This study was approved by the Ethics Committee II of the Heidelberg University (210-245 N-MA, Mannheim, Germany). Informed consent was obtained from all individual participants included in the study.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Physics, Medical and Biological Physics, Technical University Dortmund, Emil-Figge-Str. 50, 44227 Dortmund, Germany. <sup>2</sup>Department of Chemistry, University of Konstanz, Universitätsstr. 10, 78457 Constance, Germany. <sup>3</sup>University Medical Centre Hamburg-Eppendorf, Centre for Internal Medicine, Martinistr. 52, 20246 Hamburg, Germany. <sup>4</sup>Department of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. <sup>5</sup>Department of Materials Science and Engineerin, Massachusetts Institute of Technology, 400 Technology Sq. (NE46-605), Cambridge, MA 02139, USA. <sup>6</sup>Heidelberg University, Medical Faculty Mannheim, Experimental Dermatology, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.

Received: 23 February 2020 Accepted: 26 August 2020

Published online: 11 September 2020

### References

- Alexander-Katz A, Schneider MF, Schneider SW, Wixforth A, Netz RR. Shear-flow-induced unfolding of polymeric globules. *Phys Rev Lett*. 2006;97(13):138101.
- Barg A, Ossig R, Goerge T, Schneider MF, Schillers H, Oberleithner H, et al. Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network. *Thromb Haemost*. 2007;97(4):514–26.
- Mendolicchio GL, Ruggeri ZM. New perspectives on von Willebrand factor functions in hemostasis and thrombosis. *Semin Hematol*. 2005;42(1):5–14.
- Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. *Best Pract Res Clin Haematol*. 2001;14(2):257–79.
- Ruggeri ZM. Platelets in atherothrombosis. *Nat Med*. 2002;8(11):1227–34.
- Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reiningger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. *Blood*. 2006;108(6):1903–10.
- Ruggeri ZM. The role of von Willebrand factor in thrombus formation. *Thromb Res*. 2007;120(Suppl 1):S5–9.
- Sadler JE. Biochemistry and genetics of von Willebrand factor. *Annu Rev Biochem*. 1998;67:395–424.
- Schneider SW, Nuschele S, Wixforth A, Gorzelanny C, Alexander-Katz A, Netz RR, et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. *Proc Natl Acad Sci*. 2007;104(19):7899–903.
- Papi M, Maulucci G, De Spirito M, Missori M, Arcovito G, Lancellotti S, et al. Ristocetin-induced self-aggregation of von Willebrand factor. *Eur Biophys J*. 2010;39(12):1597–603.
- Campbell V, Marriott K, Stanbridge R, Shlebak A. Successful aortic aneurysm repair in a woman with severe von Willebrand (type 3) disease. *Case Rep Hematol*. 2015;2015:703803.
- Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). *Blood*. 2008;111(10):4979–85.
- Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. *J Thromb Haemost*. 2011;9:209–15.
- Kasatkar P, Ghosh K, Shetty S. An atypical manifestation of acquired von Willebrand syndrome (AVWS) associated with systemic lupus erythematosus (SLE). *Ann Hematol*. 2013;93:173–5.
- Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-Centre cohort study. *J Thromb Haemost*. 2008;6(4):569–76.
- Mannucci PM. von Willebrand factor: a marker of endothelial damage? *Arterioscler Thromb Vasc Biol*. 1998;18(9):1359–62.
- Moake JL. The role of von Willebrand factor (vWF) in thrombotic thrombocytopenic purpura (TTP) and the hemolytic-uremic syndrome (HUS). *Prog Clin Biol Res*. 1990;337:135–40.
- Wagner DD. Cell biology of von Willebrand factor. *Annu Rev Cell Biol*. 1990;6:217–46.
- Springer TA. Biology and physics of von Willebrand factor concatamers. *J Thromb Haemost*. 2011;9(Suppl 1):130–43.
- Chen H, Fallah MA, Huck V, Angerer JI, Reiningger AJ, Schneider SW, et al. Blood-clotting-inspired reversible polymer-colloid composite assembly in flow. *Nat Commun*. 2013;4:1333.
- Aponte-Santamaria C, Huck V, Posch S, Bronowska AK, Grassle S, Brehm MA, et al. Force-sensitive autoinhibition of the von Willebrand factor is mediated by interdomain interactions. *Biophys J*. 2015;108(9):2312–21.
- Auton M, Sowa KE, Behymer M, Cruz MA. N-terminal flanking region of A1 domain in von Willebrand factor stabilizes structure of A1A2A3 complex and modulates platelet activation under shear stress. *J Biol Chem*. 2012;287(18):14579–85.
- Ulrichs H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, et al. Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. *J Biol Chem*. 2006;281(8):4699–707.

24. Martin C, Morales LD, Cruz MA. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. *J Thromb Haemost.* 2007;5(7):1363–70.
25. Yuan H, Deng N, Zhang S, Cao Y, Wang Q, Liu X, et al. The unfolded von Willebrand factor response in bloodstream: the self-association perspective. *J Hematol Oncol.* 2012;5:65.
26. Ulrichs H, Vanhoorelbeke K, Girma JP, Lenting PJ, Vauterin S, Deckmyn H. The von Willebrand factor self-association is modulated by a multiple domain interaction. *J Thromb Haemost.* 2005;3(3):552–61.
27. Colace TV, Diamond SL. Direct observation of von Willebrand factor elongation and fiber formation on collagen during acute whole blood exposure to pathological flow. *Arterioscler Thromb Vasc Biol.* 2013;33(1):105–13.
28. Zhao Y, Dong N, Shen F, Xie L, He Y, Liu F, et al. Two novel monoclonal antibodies to WF3A3 inhibit WWF-collagen and WWF-platelet interactions. *J Thromb Haemost.* 2007;5(9):1963–70.
29. Ju L, Dong JF, Cruz MA, Zhu C. The N-terminal flanking region of the A1 domain regulates the force-dependent binding of von Willebrand factor to platelet glycoprotein Ibalpha. *J Biol Chem.* 2013;288(45):32289–301.
30. Yago T, Lou J, Wu T, Yang J, Miner JJ, Coburn L, et al. Platelet glycoprotein Ibalpha forms catch bonds with human WT vWF but not with type 2B von Willebrand disease vWF. *J Clin Invest.* 2008;118(9):3195–207.
31. Huck V, Schneider MF, Gorzelanny C, Schneider SW. The various states of von Willebrand factor and their function in physiology and pathophysiology. *Thromb Haemost.* 2014;111(4):598–609.
32. Brehm MA, Huck V, Aponte-Santamaria C, Obser T, Grassle S, Oyen F, et al. von Willebrand disease type 2A phenotypes IIC, IID and IIE: a day in the life of shear-stressed mutant von Willebrand factor. *Thromb Haemost.* 2014;112(1):96–108.
33. Tangelder GJ, Slaaf DW, Arts T, Reneman RS. Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. *Am J Phys.* 1988;254(6 Pt 2):H1059–64.
34. Meyer dos Santos S, Klinkhardt U, Schneppenheim R, Harder S. Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions. *Platelets.* 2010;21(1):60–6.
35. De Ceunynck K, Rocha S, Feys HB, De Meyer SF, Uji-i H, Deckmyn H, et al. Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. *J Biol Chem.* 2011;286(42):36361–7.
36. Back LD, Radbill JR, Crawford DW. Analysis of pulsatile, viscous blood flow through diseased coronary arteries of man. *J Biomech.* 1977;10(5–6):339–53.
37. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell.* 1996;84(2):289–97.
38. Klinke R, Silbernagel S. *Lehrbuch der Physiologie.* 4th edition ed. Stuttgart, Germany: Georg Thieme Verlag KG; 2005. p. 842.
39. Pappelbaum KI, Gorzelanny C, Grassle S, Suckau J, Laschke MW, Bischoff M, et al. Ultralarge von Willebrand factor fibers mediate luminal *Staphylococcus aureus* adhesion to an intact endothelial cell layer under shear stress. *Circulation.* 2013;128(1):50–9.
40. Goerge T, Kleineruschkamp F, Barg A, Schnaeker EM, Huck V, Schneider MF, et al. Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. *Thromb Haemost.* 2007;98(2):283–6.
41. Huck V, Niemeyer A, Goerge T, Schnaeker EM, Ossig R, Rogge P, et al. Delay of acute intracellular pH recovery after acidosis decreases endothelial cell activation. *J Cell Physiol.* 2007;211(2):399–409.
42. Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. *Proc Natl Acad Sci U S A.* 2002;99(1):425–30.
43. Reininger AJ. Function of von Willebrand factor in haemostasis and thrombosis. *Haemophilia.* 2008;14(Suppl 5):11–26.
44. Riddell AF, Gomez K, Millar CM, Mellars G, Gill S, Brown SA, et al. Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor. *Blood.* 2009;114(16):3489–96.
45. Huck V, Gorzelanny C, Thomas K, Getova V, Niemeyer V, Zens K, et al. From morphology to biochemical state - intravital multiphoton fluorescence lifetime imaging of inflamed human skin. *Sci Rep.* 2016;6:22789.
46. Sing CE, Selvidge JG, Alexander-Katz A. Von Willebrand adhesion to surfaces at high shear rates is controlled by long-lived bonds. *Biophys J.* 2013;105(6):1475–81.
47. Kim J, Zhang CZ, Zhang X, Springer TA. A mechanically stabilized receptor-ligand flex-bond important in the vasculature. *Nature.* 2010;466(7309):992–5.
48. Chen H, Alexander-Katz A. Polymer-based catch-bonds. *Biophys J.* 2011;100(1):174–82.
49. Baldauf C, Schneppenheim R, Stacklies W, Obser T, Pieconka A, Schneppenheim S, et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. *J Thrombosis Haemostasis.* 2009;7(12):2096–105.
50. Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer TA. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. *Science.* 2009;324(5932):1330–4.
51. Casa LD, Deaton DH, Ku DN. Role of high shear rate in thrombosis. *J Vasc Surg.* 2015;61(4):1068–80.
52. Springer TA. von Willebrand factor, Jedi knight of the bloodstream. *Blood.* 2014;124(9):1412–25.
53. Kim J, Hudson NE, Springer TA. Force-induced on-rate switching and modulation by mutations in gain-of-function von Willebrand diseases. *Proc Natl Acad Sci U S A.* 2015;112(15):4648–53.
54. Zilker A, Engelhardt H, Sackmann E. Dynamic reflection interference contrast (Ric-) microscopy - a new method to study surface excitations of cells and to measure membrane bending elastic-moduli. *J Phys-Paris.* 1987;48(12):2139–51.
55. Rack K, Huck V, Hoore M, Fedosov DA, Schneider SW, Gompper G. Margination and stretching of von Willebrand factor in the blood stream enable adhesion. *Sci Rep.* 2017;7(1):14278.
56. Schneppenheim R, Budde U, Obser T, Brassard J, Mainusch K, Ruggeri ZM, et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. *Blood.* 2001;97(7):2059–66.
57. Tan FL, Ginsburg D. What a polyclonal antibody sees in von Willebrand factor. *Thromb Res.* 2008;121(4):519–26.
58. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. *Br Med J.* 1964;2(5402):177.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

